Miyoshi So, Hey-Hadavi Judith, Nagaoka Makoto, Tammara Brinda
Int J Clin Pharmacol Ther. 2016 Dec;54(12):966-976. doi: 10.5414/CP202659.
Fosdagrocorat (PF-04171327) is a pro-drug form of PF-00251802, a dissociated agonist of the glucocorticoid receptor, under investigation for the treatment of rheumatoid arthritis. This study investigates the pharmacokinetics (PK) of single and multiple doses of fosdagrocorat in healthy Japanese and Western volunteers, the effect of food on fosdagrocorat PK, and the effect of fosdagrocorat on bone biomarkers.
This was a phase 1, randomized, placebo-controlled, dose-escalation study. For single-escalating-dose evaluation, Japanese (n = 9) and Western (n = 9) subjects were randomized (1 : 1 : 1) to treatment sequences including 3 doses of fosdagrocorat (5, 10, or 30 mg) or placebo. For multiple-dose evaluation, Japanese subjects were randomized (3 : 1) to receive fosdagrocorat 20 mg or placebo once daily (QD) for 12 days. Subjects were aged 18 - 55 years; body mass index 17.5 - 30.5 kg/m; total body weight > 45 kg.
Following single doses of fosdagrocorat, the PK of PF-00251802 and its metabolite PF-04015475 were similar between Japanese (PF-00251802: mean area under the curve (AUC) (range across doses), 791 - 3,460 ng×h/mL; individual half-life (t) 14.1 - 28.9 hours; PF-04015475: mean AUC, 395 - 1,740 ng×h/mL; individual t 21.6 - 40.3 hours) and Western (PF-00251802: mean AUC, 750 - 4,150 ng×h/mL; individual t 17.7 - 40.4 hours; PF-04015475: mean AUC, 394 - 2,160 ng×h/mL; individual t 24.5 - 63.7 hours) subjects. Steady-state concentrations were reached within 9 days following multiple doses of fosdagrocorat. Food did not affect total exposure of PF-00251802 and PF-04015475. Multiple-dose administration of fosdagrocorat 20 mg QD resulted in suppression of bone formation markers and cortisol and increased bone resorption markers vs. placebo. Adverse events (AEs) were mild in severity and no serious AEs, deaths, or severe AEs were reported.
CONCLUSIONS: The PK profile of fosdagrocorat was similar between Japanese and Western subjects, with little effect of food on PK parameters. Fosdagrocorat was well tolerated in both Japanese and Western subjects. .
福斯可罗卡特(PF-04171327)是糖皮质激素受体解离激动剂PF-00251802的前体药物,正在进行治疗类风湿关节炎的研究。本研究调查了单剂量和多剂量福斯可罗卡特在健康日本和西方志愿者体内的药代动力学(PK)、食物对福斯可罗卡特PK的影响以及福斯可罗卡特对骨生物标志物的影响。
这是一项1期随机、安慰剂对照、剂量递增研究。对于单剂量递增评估,日本受试者(n = 9)和西方受试者(n = 9)按1:1:1随机分配至治疗序列,包括3个剂量的福斯可罗卡特(5、10或30 mg)或安慰剂。对于多剂量评估,日本受试者按3:1随机分配,每天一次(QD)接受20 mg福斯可罗卡特或安慰剂,共12天。受试者年龄在18至55岁之间;体重指数为17.5至30.5 kg/m²;总体重>45 kg。
单剂量福斯可罗卡特给药后,日本受试者(PF-00251802:曲线下平均面积(AUC)(各剂量范围),791至3460 ng×h/mL;个体半衰期(t½)14.1至28.9小时;PF-04015475:平均AUC,395至1740 ng×h/mL;个体t½ 21.6至40.3小时)和西方受试者(PF-00251802:平均AUC,750至4150 ng×h/mL;个体t½ 17.7至40.4小时;PF-04015475:平均AUC,394至2160 ng×h/mL;个体t½ 24.5至63.7小时)体内PF-00251802及其代谢产物PF-04015475的PK相似。多剂量福斯可罗卡特给药后9天内达到稳态浓度。食物不影响PF-00251802和PF-04015475的总暴露量。与安慰剂相比,每天一次(QD)多剂量给予20 mg福斯可罗卡特导致骨形成标志物和皮质醇受到抑制,骨吸收标志物增加。不良事件(AE)严重程度较轻,未报告严重AE、死亡或重度AE。
福斯可罗卡特在日本和西方受试者中的PK特征相似,食物对PK参数影响较小。福斯可罗卡特在日本和西方受试者中耐受性良好。